Sep 5, 2024   SOURCE: PR NewsWire

Late Breaking Clinical Research Coming to Heart Failure Society of America Annual Scientific Meeting September 27-30

WASHINGTON, Sept. 5, 2024 /PRNewswire/ -- The Heart Failure Society of America (HFSA) is pleased to announce the Late Breaking Clinical Research that will be presented at its Annual Scientific Meeting (ASM), September 27-30, at the Georgia World Congress Center and the new Signia by Hilton Atlanta in Atlanta, GA.

Late breaking clinical research to be featured during two plenary sessions includes results and updates from these major randomized trials:

Sunday, September 29 Plenary Session | 9:00 AM - 10:30 AM

    --  STEP-HFpEF
        --  Efficacy Of Semaglutide In Patients With Obesity And HFpEF According
            To Frailty Status: A Pooled Analysis From The STEP-HFpEF Program


        --  Effects Of Semaglutide In Patients With Obesity-related Heart
            Failure With Preserved Ejection Fraction According To The Exercise
            Function At Baseline: Insights From The STEP-HFpEF Program
    --  FINEARTS-HF
        --  Efficacy And Safety Of Finerenone In Patients With Heart Failure And
            Mildly Reduced Or Preserved Ejection Fraction And A Recent Worsening
            Heart Failure Event: The FINEARTS-HF Trial


        --  Efficacy And Safety Of Finerenone Across The Ejection Fraction
            Spectrum In Heart Failure With Mildly Reduced And Preserved Ejection
            Fraction: The FINEARTS-HF Trial
    --  HELIOS-B
        --  Exploratory Analyses From HELIOS-B, A Phase 3 Study Of Vutisiran In
            Patients With Transthyretin Amyloidosis With Cardiomyopathy
        --  Title to be announced

Monday, September 30 Plenary Session | 9:00 AM - 10:30 AM

    --  SEQUOIA-HCM


        --  Global Clinical Impact Of Aficamten In Obstructive Hypertrophic
            Cardiomyopathy: Results From SEQUOIA-HCM
    --  EMBARK-HFpEF


        --  Myosin Inhibition In Heart Failure With Preserved Ejection Fraction:
            Primary Results Of The EMBARK HFpEF Trial
    --  ARIES-HM3


        --  Impact Of Pharmacological Therapy On Hemocompatibility Following
            Left Ventricular Assist Device Implantation: An Analysis From The
            ARIES-HM3 Trial
    --  EXPANDed


        --  Atrial Secondary Mitral Regurgitation Outcomes Following Mitral
            Transcatheter Edge-to-Edge Repair With The MitraClip System
    --  HuMAIN-HFpEF
        --  A Novel Controlled Metabolic Accelerator For The Treatment Of
            Obesity-related Heart Failure With Preserved Ejection Fraction:
            HuMAIN-HFpEF Trial

Late Breaking Clinical Research showcases novel results of major randomized trials and rapidly evolving research. Leaders of the field will serve as discussants, presenting brief comments about each trial to place them in context.

Due to the quantity of remarkable trials submitted, HFSA will also feature late breaking research through Rapid Fire Oral Sessions. These Rapid Fire sessions are fast-paced and brief oral presentations spotlighting key data from late breaking clinical research. Sessions take place on Saturday, Sunday and Monday with moderated Q&A and a new topic each day.

Saturday, September 28 | Rapid Fire 1: Not Just Plug and Play: Devices and Health Technology in Heart Failure | 4:00 PM - 5:00 PM

    --  Interstitial Decongestion with Device-Based Thoracic Duct Decompression
        in Acute Decompensated Heart Failure Patients
    --  RECOVER-HFPilot Study: Synchronized Diaphragmatic Stimulation For HFrEF
        Therapy
    --  PROACTIVE HF: 12-Month Results
    --  Safety And Technical Endpoints And Accurate Volume Assessment Using An
        Implanted Inferior Vena Cava Sensor
    --  Electronic Alerts To Improve Heart Failure Therapy Throughout An
        Integrated Health System: Prompt-HF Inova
    --  Effect Of Finerenone On Kansas City Cardiomyopathy Questionnaire (KCCQ)
        Score In Heart Failure With Mildly Reduced And Preserved Ejection
        Fraction: The FINEARTS-HF Trial

Sunday, September 29 | Rapid Fire 2: Birds of a Feather: Cardio-kidney-metabolism and HFpEF | 5:15 PM - 6:15 PM

    --  Efficacy And Safety Of Finerenone According To Age In Heart Failure With
        Mildly Reduced And Preserved Ejection Fraction: The FINEARTS-HF Trial
    --  The Effects Of Burst Steroid Therapy On Short Term Decongestion In Acute
        Heart Failure: The CORTAHF Randomized, Open-Label, Pilot Trial
    --  Effects Of Exogenous Ketone Therapy On Exercise Capacity In Heart
        Failure With Preserved Ejection Fraction: KETO-HFpEF
    --  Metabolic Responses To Exercise Following Weight Loss Surgery: WTLOSS-EX
        Trial
    --  Efficacy Of A Home-Based M-Health Cardiac Rehabilitation Program Among
        Older Adults With Heart Failure With Preserved Ejection Fraction: A
        Pilot Randomized Controlled Trial
    --  Understanding The Real-World Management Of Patients With Heart Failure
        At Risk For Hyperkalemia: Initial Results From The CARE-HK In Heart
        Failure (HF) Registry
    --  Unsaturated Fatty Acids To Improve Cardiorespiratory Fitness In
        Obesity-Related Heart Failure With Preserved Ejection Fraction: The
        UFA-Preserved2 Randomized Controlled Cross-over Study

Monday, September 30 | Rapid Fire 3: See One, Do One: Emerging Therapeutic Strategies in Cardiomyopathies and Heart Failure | 10:45 AM - 11:45 AM

    --  A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel
        Group Study On The Safety And Efficacy Of Istaroxime For Pre-Cardiogenic
        Shock
    --  First In Human Gene Therapy For The Cardiomyopathy Of Friedreich Ataxia
    --  Differences In Self -care Of Heart Failure Index Among Patients With
        Heart Failure With And Without Symptom Coaching Messages: A Pilot
        Clinical Trial Study
    --  Efficacy Of Single Dose Furoscix Vs. Home Dose Furosemide In Patients
        Recently Hospitalized For Heart Failure Across Diuretic Resistance
        Strata: A Pilot Randomized Controlled Trial
    --  AuXillary OUTpatient Management Of VAD BLEEDing: The AXOUT VAD BLEED
        Pilot Study
    --  Pulmonary Artery Pressures In Relation To Serial Cardiovascular Blood
        Biomarkers In Chronic Heart Failure Patients
    --  American Registry Of Ambulatory Or Acute Decompensated Heart Failure
        (AMERICCAASS): Current Results

The meeting kicks off in just three weeks. A full schedule at a glance is available online, as well as information on the science and research and networking available at the meeting. Learn more about the meeting and register at hfsa.org/asm2024.

About the Heart Failure Society of America

The Heart Failure Society of America, Inc. (HFSA) represents the first organized effort by heart failure experts from the Americas to provide a forum for all those interested in heart function, heart failure, and congestive heart failure (CHF) research and patient care. The mission of HFSA is to provide a platform to improve and expand heart failure care through collaboration, education, innovation, research, and advocacy. HFSA members include physicians, scientists, nurses, nurse practitioners, pharmacists, trainees, other healthcare workers and patients. For more information, visit hfsa.org.

Media Contact: Laura Poko, 301-798-4493, ext. 226, lpoko@hfsa.org

View original content to download multimedia:https://www.prnewswire.com/news-releases/late-breaking-clinical-research-coming-to-heart-failure-society-of-america-annual-scientific-meeting-september-27-30-302239816.html

SOURCE Heart Failure Society of America